HCA Healthcare (NYSE:HCA) Price Target Lowered to $425.00 at JPMorgan Chase & Co.

HCA Healthcare (NYSE:HCA) had its target price lowered by equities research analysts at JPMorgan Chase & Co. from $490.00 to $425.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 4.83% from the stock’s previous close.

Several other research firms have also commented on HCA. Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 price target on shares of HCA Healthcare in a research report on Monday, July 27th. Stephens lowered their target price on HCA Healthcare from $560.00 to $530.00 and set an “overweight” rating on the stock in a report on Monday, April 27th. UBS Group lowered their price target on shares of HCA Healthcare from $635.00 to $579.00 and set a “buy” rating for the company in a report on Monday, July 27th. Raymond James Financial set a $528.00 price target on HCA Healthcare in a report on Tuesday, July 7th. Finally, Argus dropped their target price on HCA Healthcare from $560.00 to $500.00 and set a “buy” rating for the company in a research note on Monday, May 4th. Fourteen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $462.64.

HCA Healthcare Stock Performance

Shares of HCA stock traded down $1.62 during mid-day trading on Thursday, hitting $405.43. 479,151 shares of the stock were exchanged, compared to its average volume of 1,335,124. The stock’s fifty day simple moving average is $395.75 and its two-hundred day simple moving average is $444.82. HCA Healthcare has a 12-month low of $353.99 and a 12-month high of $556.52. The stock has a market capitalization of $87.78 billion, a price-to-earnings ratio of 13.57, a P/E/G ratio of 1.43 and a beta of 1.10.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Friday, July 24th. The company reported $7.59 earnings per share for the quarter, topping analysts’ consensus estimates of $7.56 by $0.03. HCA Healthcare had a negative return on equity of 244.79% and a net margin of 8.77%.The business had revenue of $20.23 billion for the quarter, compared to analysts’ expectations of $19.76 billion. During the same quarter in the prior year, the firm posted $6.84 EPS. The company’s revenue was up 8.7% compared to the same quarter last year. On average, research analysts expect that HCA Healthcare will post 29.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On HCA Healthcare

Several large investors have recently bought and sold shares of the stock. Palisade Asset Management LLC bought a new stake in HCA Healthcare during the third quarter worth approximately $26,000. MidFirst Bank bought a new position in HCA Healthcare during the second quarter valued at about $28,000. Clearstead Trust LLC acquired a new stake in HCA Healthcare in the 2nd quarter valued at about $29,000. Ares Financial Consulting LLC bought a new stake in shares of HCA Healthcare during the 4th quarter worth $31,000. Finally, Cedar Mountain Advisors LLC purchased a new position in HCA Healthcare in the 1st quarter worth about $33,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.